Researcher
Oliver Bechter
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From7 May 2012 → Today
Projects
1 - 5 of 5
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Multiplexed immunohistochemistry and digital pathology as the foundation for next-generation pathology in melanoma researchFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Next-generation pathology by MILAN: multiplex immunohistochemistry and advanced trainable image analysisFrom1 Jan 2020 → 31 Dec 2021Funding: IOF - technology validation in lab
- Preventing therapy-induced cancer stemnessFrom1 Oct 2019 → TodayFunding: IOF - technology concept exploration, BOF - projects
- Treating melanoma as an infectious diseaseFrom1 Sep 2018 → 31 Aug 2022Funding: Foundations, funds and other with scientific goal
Publications
61 - 70 of 81
- Toward Minimal Residual Disease-Directed Therapy in Melanoma(2018)
Authors: Aljosja Rogiers, Michael Dewaele, Panagiotis Karras, Daniel Brown, Maria Debiec-Rychter, Carmen Adriaens, Oliver Bechter, Joost van den Oord, Thierry Voet, Stein Aerts, et al.
Pages: 843 - + - Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report(2018)
Authors: Kevin Punie, Lawrence Bonne, Vincent Vandecaveye, Oliver Bechter
Pages: 147 - 150 - Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab(2018)
Authors: Tom van Cann, Patrick Schöffski, Paul Clement, Oliver Bechter, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, Kristiaan Nackaerts, et al.
Pages: 100 - 109 - Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors(2018)
Authors: Tom van Cann, Annelies Verbiest, Paul Clement, Oliver Bechter, Ludo Willems, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, et al.
Pages: 869 - 878 - Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE(2017)
Authors: Aljosja Rogiers, Krizia Tuand, Marguerite Stas, Veerle Boecxstaens, Maria Garmyn, Joost van den Oord, Peter Vandenberghe, Oliver Bechter
Pages: 507 - 510 - Molecular genetic and immunotherapeutic targets in metastatic melanoma(2017)
Authors: Aljosja Rogiers, Oliver Bechter, Joost van den Oord
Pages: 281 - 293 - Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial(2017)
Authors: Veerle Boecxstaens, Marguerite Stas, Kris Bogaerts, Dirk Vanderschueren, Katleen Vandenberghe, Diether Lambrechts, Oliver Bechter, Vivien Marasigan, Maria Garmyn
Pages: 562 - Whole body diffusion-weighted MRI to predict treatment outcome after one cycle of immunochemotherapy in aggressive non-Hodgkin lymphoma.(2017)
Authors: Katja De Paepe, Frederik De Keyzer, Oliver Bechter, Ciska-Anne Van Keerberghen, Olivier Gheysens, Pascal Wolter, Daan Dierickx, Ann Janssens, Gregor Verhoef, Vincent Vandecaveye
- Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination(2017)
Authors: Aljosja Rogiers, Oliver Bechter
Pages: 164 - 167 - Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma(2017)
Authors: Paul Clement, Oliver Bechter, Herlinde Dumez, Annelies Verbiest, Raf Sciot, Daphne Hompes, Erik Van Limbergen, Patrick Schöffski
Pages: 1781087